Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma

Journal of the American Academy of Dermatology

Volumn 70, Issue 6, 2014, Pages

  Harcharik, Sara ^a   Bernardo, Sebastian ^a   Moskalenko, Marina ^a   Pan, Michael ^a   Sivendran, Meera ^b   Bell, Heather ^a   Hall, Lawrence D ^b   Castillo Martín, Mireia ^a   Fox, Kelly ^a   Cordon Cardo, Carlos ^a   Chang, Rui ^a   Sivendran, Shanthi ^c   Phelps, Robert G ^a   Saenger, Yvonne ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c Lancaster General Health   (United States)

Author keywords

biomarker; melanoma; primary melanoma; prognosis; recurrence; survival; tumor infiltrating lymphocytes

Indexed keywords

CD2 ANTIGEN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CUTANEOUS MELANOMA; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; AGE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FACTUAL DATABASE; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MELANOMA; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SKIN NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD2; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84901234043     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.01.914     Document Type: Article

References (29)

1. R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Maariotto, and T. Smith et al. Cancer treatment and survivorship statistics CA Cancer J Clin 62 2012 220 241
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
3. L. Ben-Porat, K.S. Panageas, C. Hanlon, A. Patel, A. Halpern, A.N. Houghton, and D. Coit Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma Cancer 106 2006 163 171
4. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, and D.R. Byrd et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
5. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, S. Ding, and D.R. Byrd et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol 28 2010 2452 2459
6. S.J. Soong, H.M. Shaw, C.M. Balch, W.H. McCarthy, M.M. Urist, and J.Y. Lee Predicting survival and recurrence in localized melanoma: a multivariate approach World J Surg 16 1992 191 195
7. S.J. Soong, R.A. Harrison, W.H. McCarthy, M.M. Urist, and C.M. Balch Factors affecting survival following local, regional, or distant recurrence from localized melanoma J Surg Oncol 67 1998 228 233
8. A.C. Green, P. Baade, M. Coory, J.F. Aitken, and M. Smithers Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia J Clin Oncol 30 2012 1462 1467
9. M. Aris, M.M. Barrio, and J. Mordoh Lessons from cancer immunoediting in cutaneous melanoma Clin Dev Immunol 2012 2012 192719
10. F. Azimi, R.A. Scolyer, P. Rumcheva, M. Moncrieff, R. Murali, and S.W. McCarthy et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma J Clin Oncol 30 2012 2678 2683
11. L. Monshizadeh, M. Hanikeri, T.W. Beer, and P.J. Heenan A critical review of melanoma pathology reports for patients referred to the Western Australian Melanoma Advisory Service Pathology 44 2012 441 447
12. K. Crawford, A. Stark, B. Kitchens, K. Sternheim, V. Pantazopoulos, and E. Triantafellow et al. CD2 engagement induces dendritic cell activation: implications for immune surveillance and T-cell activation Blood 102 2003 1745 1752
13. E.V. Tibaldi, R. Salgia, and E.L. Reinherz CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance Proc Natl Acad Sci U S A 99 2002 7582 7587
14. M. Sabry, M. Tsirogianni, I.A. Bakhsh, J. North, J. Sivakumaran, and K. Giannopoulos et al. Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors J Immunol 187 2011 6227 6234
15. B.E. Bierer, A. Peterson, J.C. Gorga, S.H. Herrmann, and S.J. Burakoff Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor J Exp Med 168 1988 1145 1156
16. P. Moingeon, H.C. Chang, B.P. Wallner, C. Stebbins, A.Z. Frey, and E.L. Reinherz CD2-mediated adhesion facilitates T lymphocyte antigen recognition function Nature 339 1989 312 314
17. D. Bogunovic, D.W. O'Neill, I. Belitskaya-Levy, V. Vacic, Y.L. Yu, and S. Adams et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival Proc Natl Acad Sci U S A 106 2009 20429 20434
18. G.J. Mann, G.M. Pupo, A.E. Campain, C.D. Carter, S.J. Schramm, and S. Pianova et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma J Invest Dermatol 133 2013 509 517
19. Sivendran S, Chang R, Pham L, Pelps R, Harcharik S, Hall L, et al. Dissection of gene networks in primary melanoma tumors critical for anti-tumor surveillance in patients with stage II-III resectable disease. J of Invest Derm doi: 10.1038/jid.2014.85. Published online February 12, 2014.
20. M. Patarroyo, J. Prieto, J. Rincon, T. Timonen, C. Lundberg, and L. Lindbom et al. Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology Immunol Rev 114 1990 67 108
21. A. Wang, F. Batteux, and E.K. Wakeland The role of SLAM/CD2 polymorphisms in systemic autoimmunity Curr Opin Immunol 22 2010 706 714
22. S.B. Prabhu, P. Gupta, H. Durgapal, S. Rath, S.D. Gupta, S.K. Acharya, and S.K. Panda Study of cellular immune response against hepatitis E virus (HEV) J Viral Hepat 18 2011 587 594
23. M.C. Mihm Jr., C.G. Clemente, and N. Cascinelli Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response Lab Invest 74 1996 43 47
24. U.N. Rao, S.J. Lee, W. Luo, M.C. Mihm Jr., and J.M. Kirkwood Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials Am J Clin Pathol 133 2010 646 653
25. U. Leiter, P.G. Buettner, T.K. Eigentler, E.B. Bröcker, C. Voit, and H. Gollnick et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German central malignant melanoma registry J Am Acad Dermatol 66 2012 37 45
26. M. Altomonte, A. Gloghini, G. Bertola, A. Gasparollo, A. Carbone, S. Ferrone, and M. Maio Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells Cancer Res 53 1993 3343 3348
27. D.A. Oble, R. Loewe, P. Yu, and M.C. Mihm Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma Cancer Immunol 9 2009 3
28. B. Thompson, R. Austin, M. Coory, J.F. Aitken, E. Walpole, G. Francis, and L. Fritschi Completeness of histopathology reporting of melanoma in a high-incidence geographical region Dermatology 218 2009 7 14
29. M.C. Fox, C.D. Lao, J.L. Schwartz, M.L. Frohm, C.K. Bichakjian, and T.M. Johnson Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist, part I: management of stage III disease J Am Acad Dermatol 68 2013 1.e1 1.e9 quiz 10-2